<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput xmlns:ns2="local" hits="3" offset="0" totalResults="3"><SearchResults><Drug id="24344" name="OB-101" lastModificationDate="2011-06-10T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>Texas A&amp;M University System</CompanyOriginator><ActionsPrimary><Action>IL-1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. OB-101 (CK-17) and OB-186 are interleukin-1 inhibitors which were under investigation by the University of Texas A&amp;amp;M System for the potential treatment of inflammation. Both compounds were active in the carrageenin-induced systemic inflammation model in rats and had low toxicity, causing very little irritation in ocular irritation studies in rabbits [ 331909 ].</Summary><CompaniesSecondary><Company>Texas A&amp;M University System</Company></CompaniesSecondary><IndicationsSecondary><Indication>Inflammatory disease</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>1999-07-14T00:00:00Z</AddedDate></Drug><Drug id="24343" name="dabigatran etexilate" lastModificationDate="2019-05-23T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Boehringer Ingelheim International GmbH</CompanyOriginator><CompaniesPrimary><Company>Boehringer Ingelheim International GmbH</Company><Company>Yuhan Corp</Company></CompaniesPrimary><IndicationsPrimary><Indication>Alzheimers disease</Indication><Indication>Deep vein thrombosis</Indication><Indication>Lung embolism</Indication><Indication>Mild cognitive impairment</Indication><Indication>Non alcoholic fatty liver disease</Indication><Indication>Phlebothrombosis</Indication><Indication>Stroke</Indication><Indication>Thromboembolism</Indication></IndicationsPrimary><ActionsPrimary><Action>Factor IIa antagonist</Action><Action>Protease-activated receptor-1 antagonist</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>Boehringer Ingelheim has developed and launched dabigatran etexilate (Pradaxa; Prazaxa Rendix; Pradax; BIBR-1048), an orally active prodrug of the thrombin (Factor IIa) inhibitor dabigatran (BIBR-953, BIBR-953ZW). The product is indicated in the US to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for</Summary><IndicationsSecondary><Indication>Embolism</Indication><Indication>Heart valve disease</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiarrhythmic agent</Action></ActionsSecondary><AddedDate>1999-07-14T00:00:00Z</AddedDate></Drug><Drug id="24342" name="topical p38 MAP kinase inhibitors (dermatitis), LEO Pharma" lastModificationDate="2008-06-27T00:00:00Z" phaseHighest="No Development Reported"><CompanyOriginator>LEO Pharma A/S</CompanyOriginator><ActionsPrimary><Action>p38 MAP kinase inhibitor</Action></ActionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>As no development has been reported for some time, this program is assumed to be discontinued. LEO Pharma was investigating selective p38alpha MAP kinase inhibitors, including EO-1428, for the potential topical treatment of dermatitis [ 331667 ], [ 422941 ]. LEO was also developing the oral p38 MAP kinase inhibitor LEO-15520 for various inflammatory conditions.</Summary><CompaniesSecondary><Company>LEO Pharma A/S</Company></CompaniesSecondary><IndicationsSecondary><Indication>Dermatitis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Dermatological agent</Action></ActionsSecondary><AddedDate>1999-07-14T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="0" label="&lt; 100"></FilterOption><FilterOption count="0" label="≥ 100 and  250"></FilterOption><FilterOption count="0" label="≥ 250 and  500"></FilterOption><FilterOption count="0" label="≥ 500 and  1000"></FilterOption><FilterOption count="1" label="≥ 1000"></FilterOption></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="3"><FilterOption id="2953" count="2" label="Anti-inflammatory"></FilterOption><FilterOption id="449" count="1" label="Antiarrhythmic agent"></FilterOption><FilterOption id="1880" count="1" label="Dermatological agent"></FilterOption></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="3"><FilterOption id="5" count="1" label="Drug - Commercialization License"></FilterOption><FilterOption id="7" count="1" label="Drug - Development Services"></FilterOption><FilterOption id="6" count="1" label="Drug - Manufacturing/Supply"></FilterOption></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="0" label="&lt; 100"></FilterOption><FilterOption count="0" label="≥ 100 and  250"></FilterOption><FilterOption count="0" label="≥ 250 and  500"></FilterOption><FilterOption count="0" label="≥ 500 and  1000"></FilterOption><FilterOption count="0" label="≥ 1000"></FilterOption></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="2" label="= 0"></FilterOption><FilterOption count="0" label="&gt; 1 and ≤ 1"></FilterOption><FilterOption count="0" label="&gt; 2 and ≤ 2"></FilterOption><FilterOption count="1" label="&gt; 3 and ≤ 3"></FilterOption><FilterOption count="0" label="&gt; 4 and ≤ 4"></FilterOption><FilterOption count="0" label="&gt; 5 and ≤ 5"></FilterOption><FilterOption count="0" label="&gt; 6 and ≤ 10"></FilterOption><FilterOption count="0" label="&gt; 11"></FilterOption></Filter><Filter label="Technologies" name="technologies" total="6"><FilterOption id="762" count="3" label="Small molecule therapeutic"></FilterOption><FilterOption id="586" count="1" label="Capsule formulation"></FilterOption><FilterOption id="611" count="1" label="Dermatological formulation"></FilterOption><FilterOption id="585" count="1" label="Oral formulation"></FilterOption><FilterOption id="1652" count="1" label="Prodrug"></FilterOption><FilterOption id="595" count="1" label="Tablet formulation"></FilterOption></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="1"><FilterOption count="3" label="1999-07-14"></FilterOption></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="2" label="No"></FilterOption><FilterOption count="1" label="Yes"></FilterOption></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="2"><FilterOption id="17774" count="1" label="LEO Pharma A/S"></FilterOption><FilterOption id="23290" count="1" label="Texas A&amp;M University System"></FilterOption></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="8"><FilterOption id="14" count="1" label="Alzheimers disease"></FilterOption><FilterOption id="574" count="1" label="Deep vein thrombosis"></FilterOption><FilterOption id="1078" count="1" label="Lung embolism"></FilterOption><FilterOption id="3122" count="1" label="Mild cognitive impairment"></FilterOption><FilterOption id="3288" count="1" label="Non alcoholic fatty liver disease"></FilterOption><FilterOption id="1845" count="1" label="Phlebothrombosis"></FilterOption><FilterOption id="65" count="1" label="Stroke"></FilterOption><FilterOption id="325" count="1" label="Thromboembolism"></FilterOption></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="4"><FilterOption id="94" count="1" label="Dermatitis"></FilterOption><FilterOption id="1077" count="1" label="Embolism"></FilterOption><FilterOption id="1562" count="1" label="Heart valve disease"></FilterOption><FilterOption id="188" count="1" label="Inflammatory disease"></FilterOption></Filter><Filter label="Primary Actions" name="actionsPrimary" total="4"><FilterOption id="111" count="1" label="Factor IIa antagonist"></FilterOption><FilterOption id="218" count="1" label="IL-1 receptor antagonist"></FilterOption><FilterOption id="2419" count="1" label="p38 MAP kinase inhibitor"></FilterOption><FilterOption id="11192" count="1" label="Protease-activated receptor-1 antagonist"></FilterOption></Filter><Filter label="Primary Companies" name="companiesPrimary" total="2"><FilterOption id="14881" count="1" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="20984" count="1" label="Yuhan Corp"></FilterOption></Filter><Filter label="Highest Phase" name="phaseHighest" total="2"><FilterOption id="NDR" count="2" label="No Development Reported"></FilterOption><FilterOption id="L" count="1" label="Launched"></FilterOption></Filter></Filters></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput>